Philadelphia, PA (PRWEB) April 24, 2015
Olfactory Biosciences Corp. (OLFC) (OTC) is pleased to introduce Sensopath™, a topical preparation for autism spectrum disorder (ASD) related information integration issues. The Sensopath™ preparation is made with natural ingredients, and is effective using advanced olfaction and chemoreception. Applying Sensopath™ topical medicine is just rubbing a small amount of the preparation to the end of your nostrils.
Many people have difficulty processing everyday sensory information; this is usually called having Sensory Integration Difficulties such as those with an Autism Spectrum Disorder (ASD). Sensopath™ can have a beneficial effect on these sensory issues. Sensopath™ molecules work by transporting their “messages” directly to the brain’s limbic system, which can change behavior. People with sensory integration difficulties – including many people with ASD – have difficulty processing everyday sensory information.
New Sensopath™ can offer relief from environmental as well as everyday sensory challenges that have the potential to trigger coping responses. It may also strengthen cognitive weakness across the wide range of sensory integration disorders.
Sensopath™ may also improve moderate attention deficits like ADD or ADHD since molecules transport their “messages” directly to the brain’s limbic system for improved focus and attention. Sensory issues are on the rise and Sensopath™ is needed more than ever. For additional information https://noxoinfo.com/product/sensory/
Olfactory receptors are nerves and neurotransmitters and act by attaching to the company's natural ingredients. Olfactory Biosciences uses a new topical innovative delivery system, the company's own tested science and that of the NOBEL Prize winners in Medicine 2004. For more information go to https://noxoinfo.com/product/sensory/
Ingredients: See https://www.noxoinfo.com
Each Sensopath™ preparation comes in a 3 oz.tin. (about 100 doses or applications)
About Olfactory Biosciences Corp.
Olfactory Biosciences Corp. develops products targeting olfactory receptors in the nose for the desired effect. These topical medicine preparations include: HungerMgmt™ for relief from cravings and overeating: Exanstres™ for stress: Somaklin™ for anxiety, panic and help with PTSD: Sambigan™, for a good night’s natural sleep: Nootravate ™, to improve your memory: Studibuddy™, a natural way to excel with memory enhancement.: Emoodal ™, for the best best Mood in a calm-energy state and NOXO Odor Defense Pro™, the best way to relieve the distress and symptoms associated with noxious and bad odors.. https://www.noxoinfo.com/
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA